Geoffrey W. Smith

Founder / Managing Partner

Companies

  • CareDox

  • Elemental Machines

  • Girihlet

  • GRO Biosciences

  • Second Genome

Geoff is the founder and Managing Partner of Digitalis.

He is also a co-founder and General Partner of Ascent Biomedical Ventures, a New York City-based venture capital firm focused on early-stage life sciences investments. Geoff currently represents Ascent on the Board of Directors for Azevan Pharmaceuticals, BlinkBio, and Orchestra BioMed, and is a Board Observer of Vivasure Medical.

Geoff serves as a Trustee of The Jackson Laboratory. He is a Visiting Scholar at Rockefeller University and an adjunct faculty member at the RU Center for Clinical and Translational Science. Geoff also serves as a member of the Scientific Advisory Board for Brigham & Women’s Hospital in Boston. Previously, he was the founding Director of the Mount Sinai Institute of Technology and a Professor in the Department of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai.

Geoff received a B.A. (with honors) from Williams College and a J.D. from the University of Pennsylvania Law School.

Geoffrey W. Smith

Founder / Managing Partner

Steve Allen

Partner

Companies

  • Kenzen

  • Second Genome

Steve is a Partner at Digitalis.

Previously, Steve was Chairman of the Board of Chromadex Corp. (Nasdaq: CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food, beverage and cosmetic companies. He is past President and Member of the Board of the North American Foundation for the University of Leeds where he obtained a B.Sc. degree. He also has a M.Sc. from the School of Hygiene & Tropical Medicine at the University of London. Most of Steve’s working career was with Nestlé where he worked in nutrition businesses in several countries and in corporate venturing. Steve co-founded and is a member of the Screening Committee of Nutrition Capital Network, a business that brings together entrepreneurs and investors in the nutrition and food industries.

Steve Allen

Partner

Drew Taylor

Partner

Companies

  • Scratchpay

  • Somatix

Drew is a Partner at Digitalis.

Previously, Drew was the Head of New Ventures at Taylor Farms, the world’s largest processor of fresh-cut fruits and vegetables. During this time he led the creation and investment activity of Taylor Ventures, which invests in early-stage food and ag technology companies.

Drew represents Taylor Ventures on the Board of Directors at HarvestPort and served in a variety of operational roles with Taylor Farms. He also served on the board of the “Let’s Move Salad Bars to Schools” campaign in partnership with Michelle Obama’s “Let’s Move” initiative. Drew received his BA from Stanford University and MBA from Harvard Business School.

Drew Taylor

Partner

Cindy Cole

Technical Partner

Cindy is a Technical Partner at Digitalis.

She received her DVM and Ph.D. in cardiovascular pharmacology from the University of Florida. She has served on the faculty of UC Davis and is currently an Associate Clinical Professor and Director of the Racing Laboratory at the University of Florida. Cindy is also a diplomate of the American College of Veterinary Clinical Pharmacology. Prior to joining Digitals, she held R&D and management roles with IDEXX, Novartis Animal Health, Piedmont Pharmaceuticals and Mars Petcare.

Cindy Cole

Technical Partner

Dac Nguyen

Technical Partner

Dac is a Technical Partner at Digitalis. He received his Ph.D. in biophysics from Mount Sinai and A.B. in physics from Harvard. His interests include physical and computational approaches to problems in biophysics, genomics and synthetic biology.

Dac Nguyen

Technical Partner

Amit Bansal

Principal

Companies

  • CareDox

  • Somatix

Amit is a Principal at Digitalis.

Amit is on the board of the Fund for Public Health NYC, an independent, nonprofit organization that connects the NYC Health Department with public and private sector partners to build public health programs. Prior to Digitalis, Amit was at Mars, Inc. in both corporate strategy and corporate innovation roles. Most recently, he was responsible for developing the business model for a new unit focused on affordable nutrition in the developing world. Amit has also worked in rural healthcare in India at Piramal E-swasthya, a start-up leveraging telemedicine to provide last mile access to primary care. Amit began his career at GE Healthcare in corporate finance, where he held a number of roles in finance, risk, and marketing. He received his M.B.A. from Northwestern University’s Kellogg School of Management and his B.A. from Boston College.

Amit Bansal

Principal

Samuel Bjork

Principal

Companies

  • Elemental Machines

  • Rejuvenate Bio

Samuel is a Principal at Digitalis.

He received graduate degrees from Cambridge and Oxford University as a Marshall Scholar and an A.B. in Chemistry from Harvard University. Prior to Digitalis, Samuel was a member of the healthcare and clean energy practices at the Boston Consulting Group.

Samuel Bjork

Principal

Jonathan Friedlander

Principal

Jonathan is a Principal at Digitalis.

He received his PhD in cell biology from the University of Cambridge and an MBA from Harvard Business School. Prior to Digitalis, Jonathan was an associate at Flagship Pioneering where he worked on the creation of biotech companies for human therapeutics and agriculture.

Jonathan Friedlander

Principal

Amber Kulak

Controller

Amber is the Controller at Digitalis.

Prior to joining Digitalis, Amber was a fund controller at Schroder Adveq and a senior accountant at Atlas Venture. Amber began her career in public accounting at Ernst & Young and RSM US. She earned her M.S., Accounting and B.S., Accounting from the University of Massachusetts, Amherst. She is also a Certified Public Accountant.

Amber Kulak

Controller

Casey Brooks

Research Associate

Casey is a Research Associate at Digitalis.

Prior to joining Digitalis, she received her B.A. in genomics and computational biology from Washington University in St. Louis. At Wash U, Casey completed over 1,100 hours of service as an EMT and led a digital health venture for stroke rehabilitation. Casey also spent time at the Icahn School of Medicine at Mount Sinai (NYC) doing research in the department of OBGYN-Maternal Fetal Medicine on the subject of adverse pregnancy outcomes given certain biochemical markers.

Casey Brooks

Research Associate

Advisors

Carlos Bustamante

Advisor

Carlos Bustamante is a population geneticist whose research focuses on analyzing genome wide patterns of variation within and between species to address fundamental questions in biology, anthropology, and medicine. From 2002-2009, he was on the faculty at Cornell University, in the Departments of Statistical Sciences and Biology Statistics and Computational Biology, where he was promoted to full professor in 2008. Since 2010, he has been on the faculty in the Department of Genetics at the Stanford University School of Medicine. In 2015, he was appointed the Inaugural Chair of Stanford's new Department of Biomedical Data Science.

He has received multiple honors and awards including a Marshall-Sherfield Fellowship (2001-2), the Sloan Research Fellowship (2007), and a John D. and Catherine T. MacArthur Fellowship (2010). He has trained over 50 post-doctoral fellows and graduate students as primary advisor and co-authored over 130 papers. Much of his research is located at the interface of computational biology, mathematical genetics, and evolutionary genomics. His most current research focuses on human population genomics and global health including developing statistical, computational, and genomic resources for enabling trans- and multi-ethnic genome-wide association and medical sequencing studies of complex biomedical traits. He is one of the Principal Investigators of the recently announced $25M ClinGen project to build the country's National Database of Clinically Relevant Genomic Variants. He has advised multiple companies, non-profits, and government bodies in the past including Mars, Inc., Ancestry.com,Personalis, Inc., the National Human Genome Research Institute, and the Carlos Slim Foundation.

Carlos Bustamante

Advisor

Brian Naughton

Advisor

Dr. Brian Naughton is Founder and Head of Data at Hexagon Bio, a computational and synthetic biology drug development company. At Hexagon, Brian works on genome analysis, computational synthetic biology, and drug screening. Before that, Brian was Founding Scientist and Vice President at 23andMe. In this role, he drew on his experience in bioinformatics, statistics and genetics to analyze data, develop algorithms, and translate scientific research to drive the world's first Personal Genome Service.

Dr. Naughton earned a PhD from the Biomedical Informatics program at Stanford University and a BA in Human Genetics from Trinity College, Dublin.

Brian Naughton

Advisor

Glen Nedwin

Advisor

Dr. Nedwin has over 30 years experience in the pharmaceutical and industrial biotechnology industries. He is an accomplished senior executive with domestic and international experience in new market identification, innovation, research & development, business planning, strategic positioning, operations, P&L, sales & marketing, involving both start-up, growth and billion dollar organizations. He has a track record of innovative product development, market focus, increasing sales and EBIT while spearheading operational improvements to drive productivity and increase efficiency.

Dr. Nedwin received his B.S. degree in Biochemistry from S.U.N.Y./Buffalo and a Ph.D. in Biochemistry from U.C. Riverside. He did a post-doctoral fellowship in Molecular Biology at Genentech, Inc. Dr. Nedwin also holds a M.S. Degree in the Management of Technology from the Massachusetts Institute of Technology. Dr. Nedwin has held a number of varied scientific, corporate development and senior management positions, most notably as President of Novozymes, Inc., and as Executive Vice President of the Genencor Technical Enzymes Division of Danisco (acquired by DuPont in 2011). More recently, Dr. Nedwin was CEO of Taxon Biosciences, Inc., (acquired by DuPont in April 2015) and the former CEO of Second Genome.

Dr. Nedwin is currently CEO of TripleDNA Consulting, LLC. He is a co-author of over 40 scientific publications and patents and the former co-editor in chief of the journal Industrial Biotechnology. Dr. Nedwin has served on several Boards, including the UC Davis Foundation Board of Trustees. He is a former and founding member of the Board of Executives of the UCD Robert Mondavi Institute of Wine and Food Science. Dr. Nedwin is also an accomplished rock and blues guitarist, as well as a luthier.

Glen Nedwin

Advisor

John Wilbanks

Advisor

John Wilbanks is the Chief Commons Officer at Sage Bionetworks and a Senior Fellow at Faster Cures.

Previously, Wilbanks worked as a legislative aide to Congressman Fortney "Pete" Stark, served as the first assistant director at Harvard's Berkman Center for Internet & Society, founded and led to acquisition the bioinformatics company Incellico, Inc., and was executive director of the Science Commons project at Creative Commons. In February 2013, in response to a We the People petition that was spearheaded by Wilbanks and signed by 65,000 people, the U.S. government announced a plan to open up taxpayer-funded research data and make it available for free. Wilbanks holds a B.A. in philosophy from Tulane University and also studied modern letters at the Sorbonne.

John Wilbanks

Advisor

Network

Digitalis Commons

Established as the non-profit arm of Digitalis, the Commons provides capital, expertise, and an institutional home for projects and groups building open solutions and other public goods to address complex problems in healthcare. Coming Soon.

Experts

The distributed Digitalis network comprises experts from a wide range of functional areas — including clinical development, regulatory, design, communications, and recruiting — and technical domains relevant to human and animal health.

Fellows

Digitalis Fellows work with our team to discover, build, and fund transformative new technologies and businesses. Fellows are integrated into Digitalis on a flexible and rotating schedule and are drawn from technical and professional fields relevant to our portfolio.